Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

Label-Free Monitoring of μ-Opioid Receptor–Mediated Signaling

Philippe Bourassa, Hanieh Bagheri Tudashki, Graciela Pineyro, Michel Grandbois and Louis Gendron
Molecular Pharmacology August 2014, 86 (2) 138-149; DOI: https://doi.org/10.1124/mol.114.093450
Philippe Bourassa
Départements de Physiologie et Biophysique (P.B., L.G.), Pharmacologie (H.B.T., M.G.), and Psychiatrie (G.P.), Centre de Recherche du CHU Ste-Justine (H.B.T, G.P.), Université de Montréal, Montreal, Quebec, Canada; Institut de Pharmacologie de Sherbrooke (M.G., L.G.), Centre de Recherche du CHU Sherbrooke (P.B., M.G., L.G.), Université de Sherbrooke (P.B., M.G., L.G.), Sherbrooke, Quebec, Canada; and Quebec Pain Research Network, Quebec City, Quebec, Canada (L.G.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hanieh Bagheri Tudashki
Départements de Physiologie et Biophysique (P.B., L.G.), Pharmacologie (H.B.T., M.G.), and Psychiatrie (G.P.), Centre de Recherche du CHU Ste-Justine (H.B.T, G.P.), Université de Montréal, Montreal, Quebec, Canada; Institut de Pharmacologie de Sherbrooke (M.G., L.G.), Centre de Recherche du CHU Sherbrooke (P.B., M.G., L.G.), Université de Sherbrooke (P.B., M.G., L.G.), Sherbrooke, Quebec, Canada; and Quebec Pain Research Network, Quebec City, Quebec, Canada (L.G.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Graciela Pineyro
Départements de Physiologie et Biophysique (P.B., L.G.), Pharmacologie (H.B.T., M.G.), and Psychiatrie (G.P.), Centre de Recherche du CHU Ste-Justine (H.B.T, G.P.), Université de Montréal, Montreal, Quebec, Canada; Institut de Pharmacologie de Sherbrooke (M.G., L.G.), Centre de Recherche du CHU Sherbrooke (P.B., M.G., L.G.), Université de Sherbrooke (P.B., M.G., L.G.), Sherbrooke, Quebec, Canada; and Quebec Pain Research Network, Quebec City, Quebec, Canada (L.G.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michel Grandbois
Départements de Physiologie et Biophysique (P.B., L.G.), Pharmacologie (H.B.T., M.G.), and Psychiatrie (G.P.), Centre de Recherche du CHU Ste-Justine (H.B.T, G.P.), Université de Montréal, Montreal, Quebec, Canada; Institut de Pharmacologie de Sherbrooke (M.G., L.G.), Centre de Recherche du CHU Sherbrooke (P.B., M.G., L.G.), Université de Sherbrooke (P.B., M.G., L.G.), Sherbrooke, Quebec, Canada; and Quebec Pain Research Network, Quebec City, Quebec, Canada (L.G.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Louis Gendron
Départements de Physiologie et Biophysique (P.B., L.G.), Pharmacologie (H.B.T., M.G.), and Psychiatrie (G.P.), Centre de Recherche du CHU Ste-Justine (H.B.T, G.P.), Université de Montréal, Montreal, Quebec, Canada; Institut de Pharmacologie de Sherbrooke (M.G., L.G.), Centre de Recherche du CHU Sherbrooke (P.B., M.G., L.G.), Université de Sherbrooke (P.B., M.G., L.G.), Sherbrooke, Quebec, Canada; and Quebec Pain Research Network, Quebec City, Quebec, Canada (L.G.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

In this study, we used a combination of traditional signaling investigation approaches, bioluminescence resonance energy transfer (BRET) biosensors, and the label-free approach surface plasmon resonance (SPR) spectroscopy to monitor the signaling cascades of the μ-opioid receptor (MOP). In human embryonic kidney cells stably expressing a Flag-tagged version of human MOP, we compared the signals triggered by the noninternalizing and internalizing MOP agonists morphine and DAMGO (Tyr-d-Ala-Gly-N-methyl-Phe-Gly-ol), respectively. We studied three major and well described components of MOP signaling: receptor internalization, G protein coupling, and activation of extracellular signal-regulated kinase ERK1/ERK2. Our results show that morphine and DAMGO display different profiles of receptor internalization and a similar ability to trigger the phosphorylation of ERK1/ERK2. Our SPR analyses revealed that morphine and DAMGO evoke similar SPR signatures and that Gαi, cAMP-dependent pathways, and ERK1/ERK2 have key roles in morphine- and DAMGO-mediated signaling. Most interestingly, we found that the so-called MOP neutral antagonists CTOP (d-Phe-Cys-Tyr-d-Trp-Orn-Thr-Pen-Thr-NH2), naloxone, and naltrexone behave like partial agonists. Even more intriguing, BRET experiments indicate that CTAP (d-Phe-Cys-Tyr-d-Trp-Arg-Thr-Pen-Thr-NH2) induces similar conformational changes as naltrexone at the Gαi-βγ interface, whereas it appears as an inverse agonist based on its SPR response thus indicating distinct signaling mechanisms for the two ligands. Taken together, our results support the usefulness of label-free methods such as SPR to study whole-cell responses and signaling cascades triggered by G protein–coupled receptors and complement the conventional approaches by revealing cellular responses that would have been otherwise undetectable.

Footnotes

    • Received April 24, 2014.
    • Accepted May 29, 2014.
  • This research was supported by a Collaborative Health Research Project grant from the Natural Sciences and Engineering Research Council of Canada and the Canadian Institutes of Health Research [Grants RPCS-385882-2010 (to M.G. and L.G.) and 311997 (to G.P.)] and the Fonds de Recherche Québec–Santé [Junior 2 salary support (to L.G.) and a Master scholarship (to P.B.)]. M.G. holds the Tier 2 Canada Research Chair in Nanopharmacology and Atomic Force Microscopy.

  • This work was previously presented in part at the following workshop: Bourassa P, Grandbois M, Gendron L (2013) Surface plasmon resonance as a tool to assess functional selectivity at the mu opioid receptor. 43rd Annual Meeting for the Society for Neuroscience; 2013 Nov 9–13; San Diego, CA.

  • dx.doi.org/10.1124/mol.114.093450.

  • Copyright © 2014 by The American Society for Pharmacology and Experimental Therapeutics
View Full Text

MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Molecular Pharmacology: 86 (2)
Molecular Pharmacology
Vol. 86, Issue 2
1 Aug 2014
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Label-Free Monitoring of μ-Opioid Receptor–Mediated Signaling
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Surface Plasmon Resonance to Assess Signaling Cascades

Philippe Bourassa, Hanieh Bagheri Tudashki, Graciela Pineyro, Michel Grandbois and Louis Gendron
Molecular Pharmacology August 1, 2014, 86 (2) 138-149; DOI: https://doi.org/10.1124/mol.114.093450

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Surface Plasmon Resonance to Assess Signaling Cascades

Philippe Bourassa, Hanieh Bagheri Tudashki, Graciela Pineyro, Michel Grandbois and Louis Gendron
Molecular Pharmacology August 1, 2014, 86 (2) 138-149; DOI: https://doi.org/10.1124/mol.114.093450
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Mechanism of the selective action of paraherquamide A
  • Use-Dependent Relief of A-887826 Inhibition
  • Benzbromarone Relaxes Airway Smooth Muscle via BK Activation
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics